Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VVOS

VVOS - Vivos Therapeutics, Inc. Stock Price, Fair Value and News

$1.69-0.10 (-5.59%)
Market Closed

43/100

VVOS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

43/100

VVOS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.65

Target 3M

$1.74

Target 6M

$1.71

VVOS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VVOS Price Action

Last 7 days

-7.6%

Last 30 days

-16.7%

Last 90 days

-34.5%

Trailing 12 Months

-59.0%

VVOS RSI Chart

VVOS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VVOS Valuation

Market Cap

15.2M

Price/Earnings (Trailing)

-0.89

Price/Sales (Trailing)

0.88

EV/EBITDA

-1.64

Price/Free Cashflow

-0.99

VVOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.65

Target 3M

$1.74

Target 6M

$1.71

VVOS Fundamentals

VVOS Revenue

Revenue (TTM)

17.3M

Rev. Growth (Yr)

75.73%

Rev. Growth (Qtr)

77.57%

VVOS Earnings

Earnings (TTM)

-17.1M

Earnings Growth (Yr)

-106.42%

Earnings Growth (Qtr)

-7.72%

VVOS Profitability

EBT Margin

-98.77%

Return on Equity

-675.51%

Return on Assets

-66.7%

Free Cashflow Yield

-101.22%

VVOS Investor Care

Shares Dilution (1Y)

85.89%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202514.6M14.4M17.3M0
202413.4M14.0M14.6M15.0M
202316.2M15.4M14.5M13.8M
202217.1M16.8M16.5M16.0M
202113.3M14.5M15.8M16.9M
202011.8M12.2M12.6M13.1M
201900011.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Vivos Therapeutics, Inc.

VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.
 CEO
 WEBSITEhttps://vivos.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES154

Vivos Therapeutics, Inc. Frequently Asked Questions

VVOS is the stock ticker symbol of Vivos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Vivos Therapeutics, Inc. is 15.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check VVOS's fair value in chart for subscribers.

The fair value guage provides a quick view whether VVOS is over valued or under valued. Whether Vivos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Vivos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VVOS.

As of Wed Jan 28 2026, VVOS's PE ratio (Price to Earnings) is -0.89 and Price to Sales (PS) ratio is 0.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VVOS PE ratio will change depending on the future growth rate expectations of investors.